Randomized controlled trial of intraportal chemotherapy combined with adjuvant chemotherapy (mFOLFOX6) for stage II and III colon cancer. Ann Surg 2016; 263: 434-439.

Published: 2nd November 2016

Authors: Chang W, Wei Y, Ren L, Zhong Y, Yu Y, Chen J et al.

Conclusion

Some 237 patients were included and followed for a median of 44 months. Three year disease-free survival was improved by the addition of intraportal chemotherapy (85.2 versus 75.6 per cent, P=0.03), but there was no difference in overall survival.

Pubmed Link

Your comments

0 Comments